Messy.
With readout due mid year why would Sarepta exit the deal?
Probs because there is a milestone payment due as soon as results drop...and results crap.
Back to DMD and LGMD for Sarepta.
Unfortunately they have put all their eggs in the Gene Therapy basket....
...at a time when the new game in town is mRNA tech.
Pfizer this week announced more investment / partnerships in the mRNA space (Codex & Acuitas).
"We truly believe that the mRNA technology is very powerful. It's not the holy grail, but it is very powerful," Bourla said.
.
Messy. With readout due mid year why would Sarepta exit the...
Add PER (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
7.2¢ |
Change
0.004(5.88%) |
Mkt cap ! $64.91M | |||
| Open | High | Low | Value | Volume |
| 7.0¢ | 7.2¢ | 6.9¢ | $91.71K | 1.319M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 50000 | 7.1¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 7.2¢ | 18695 | 1 |
View Market Depth
| Last trade - 16.10pm 29/04/2024 (20 minute delay) ? |
|
|||||
|
Last
7.1¢ |
Change
0.004 ( 3.20 %) |
||||
| Open | High | Low | Volume | ||
| 6.9¢ | 7.2¢ | 6.9¢ | 129842 | ||
| Last updated 15.32pm 29/04/2024 ? | |||||
| PER (ASX) Chart |